EDARAVONE IN ACUTE ISCHEMIC STROKE

Phase 3

• Conditions: ISCHEMIC STROKE

• Registration Number: CTRI/2009/091/000309

Brief Summary

This is a prospective, open labeled, randomized controlled clinical trial to investigate the safety and efficacy of edaravone in terms of functional outcome in patients with acute ischemic stroke, that will be conducted in the Department of Neurology, CSM Medical University, Lucknow. the primary outcome will be modified Rankin Scale at 90 days. The secondary outcome will be all cause mortality at 90 days.

Detailed Description

Not available

Recruitment & Eligibility

• Sex: Not specified
• Target Recruitment: 52

Inclusion Criteria

Patients with acute ischemic stroke hospitalized between 6 and 72 hours of onset of stroke.

Exclusion Criteria

Patients with age less than 18 years, unclear time of onset, those who received any thrombolytic therapy, those with severe hepatic disease, renal dysfunction, pregnancy or lactating female.

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified Rankin Score	90 days

Secondary Outcome Measures

Name	Time	Method
All cause mortality	90 days

Trial Locations

Locations (1)

DEPARTMENT OF NEUROLOGY; 🇮🇳 Lucknow, UTTAR PRADESH, India

DEPARTMENT OF NEUROLOGY

🇮🇳Lucknow, UTTAR PRADESH, India

PROF. RAKESH SHUKLA

Principal investigator

05222257090

rakeshshukla_rakesh@rediffmail.com